Murray Christian A, Cohen Joel L, Solish Nowell
Division of Dermatology, University of Toronto, Women's College Hospital, Toronto, ON, Canada.
J Cutan Med Surg. 2007 Mar-Apr;11(2):67-77. doi: 10.2310/7750.2007.00012.
Focal hyperhidrosis is not rare, affecting over 2.5% of the population. This condition is often socially and professionally debilitating, leading to significant quality of life impairment. It most commonly involves the axillae, palms, soles, and face.
To review hyperhidrosis and discuss and compare the treatment options currently available.
Topical or systemic therapies may be helpful for patients with mild disease. Invasive surgical options, although often effective, are limited by complications. More recently, botulinum toxin injection has proven to be a safe and successful treatment for hyperhidrosis and results in high patient satisfaction. Botulinum toxin A (Botox, Allergan Inc., Irvine, CA) is currently approved in the United States, Canada, the United Kingdom, and many other countries for the treatment of axillary hyperhidrosis and is routinely used off-label for other anatomic sites.
局限性多汗症并不罕见，影响超过2.5%的人群。这种情况在社交和职业方面往往会造成困扰，导致生活质量显著下降。它最常累及腋窝、手掌、脚底和面部。
回顾多汗症并讨论和比较目前可用的治疗选择。
局部或全身治疗可能对轻度疾病患者有帮助。侵入性手术选择虽然通常有效，但受并发症限制。最近，肉毒杆菌毒素注射已被证明是一种安全且成功的多汗症治疗方法，患者满意度高。肉毒杆菌毒素A（保妥适，艾尔建公司，加利福尼亚州欧文市）目前在美国、加拿大、英国和许多其他国家被批准用于治疗腋窝多汗症，并经常用于其他解剖部位的非标签治疗。
Zotero 插件